Compare Citius Pharmaceuticals Inc (CTXR) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nvidia Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Nvidia Corp trades at $218.31 (market cap $5.27T). The key difference: Nvidia Corp is far larger — about 281366.8× Citius Pharmaceuticals Inc's market cap, and Nvidia Corp pays a 0.46% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NVDA | |
|---|---|---|
Market Cap | $18.73M | $5.27T |
Sector | Health | Technology |
52-Week High | $1.82 | $235.75 |
52-Week Low | $0.48 | $165.17 |
Enterprise Value | $14.95M | $5.20T |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
NVIDIA (NVDA) trades at $217.56, down 2.86% over 24 hours, amid a broader tech sell-off. The stock maintains strong fundamentals with Q1 2026 EPS beating estimates at $1.87 and a net income margin of 62.97%. Technical analysis shows a bullish trend with support at $215 and resistance at $222, while RSI indicates neutral momentum.
Outlook remains positive given robust AI-driven revenue growth and a $325.86 analyst price target, but risks include high valuation multiples and competitive pressures. The stock presents a long-term growth opportunity, though investors should monitor earnings sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
